Related Experiment Videos

Exploring the potential of PI3K inhibitors for inflammation and cancer

T Crabbe1

  • 1UCB, 216 Bath Road, Slough, UK. tom.crabbe@ucb-group.com

Biochemical Society Transactions
|March 21, 2007
PubMed

Insights

Targeting phosphoinositide 3-kinases (PI3Ks) shows promise for cancer and inflammation. This study explores PI3K isoform selectivity, evaluating risks and benefits of developing targeted therapies.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Class I phosphoinositide 3-kinases (PI3Ks) are validated targets for cancer and inflammatory diseases.
  • Achieving PI3K isoform selectivity is crucial for minimizing safety risks and maximizing therapeutic benefit.
  • The clinical utility of highly isoform-selective inhibitors versus broad-spectrum inhibitors remains uncertain.

Purpose of the Study:

  • To generate and evaluate a diverse range of PI3K inhibitors with varying isoform selectivity profiles.
  • To establish a framework for understanding how PI3K isoform selectivity impacts biological potency in disease models.
  • To assess the risks and benefits associated with developing PI3K inhibitors with limited isoform selectivity.

Main Methods:

  • Utilized pharmacophore searching and high-throughput screening to identify PI3K inhibitor scaffolds.
  • Employed medicinal chemistry to modulate compound potency and isoform selectivity.
  • Used high-throughput cell-based assays relevant to cancer and inflammation to assess biological activity.

Main Results:

  • Developed a collection of compounds with a broad spectrum of PI3K isoform inhibition.
  • Investigated two compounds: a pan-PI3K inhibitor and UCB1311236, selective for PI3Kgamma.
  • Demonstrated how isoform selectivity influences potency against other kinases and cellular activity.

Conclusions:

  • PI3K isoform selectivity is a key consideration in drug development for cancer and inflammatory conditions.
  • The study highlights the trade-offs between isoform selectivity and therapeutic efficacy.
  • Findings inform strategies for developing novel PI3K-targeted therapeutics with optimized safety and efficacy profiles.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
piRNA - Piwi-interacting RNAs02:57

piRNA - Piwi-interacting RNAs

PIWI-interacting RNAs, or piRNAs, are the most abundant short non-coding RNAs. More than 20,000 genes have been found in humans that code for piRNAs while only 2000 genes have been found for miRNAs. piRNAs can act at the transcriptional and post-transcriptional levels and have a vital role in silencing transposable elements present in germ cells. They are also involved in epigenetic silencing and activation. Previously, they were thought to function only in germ cells but new evidence suggests...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...